Translation of "translation of dans le cadre " (French → English) :

– I voted in favour of the new Framework Agreement between the Parliament and Commission.

– (LT) I support this Framework Agreement, since cooperation between the European Parliament and the European Commission is particularly important in strengthening the stability of the European Union and the effectiveness of its work.

– (PT) I voted in favour of the European Parliament resolution on a revised Framework Agreement between the European Parliament and the Commission for the next parliamentary term as it is an important agreement, not only for its symbolic value – given that it gives a clear signal of the commitment of both European institutions, Parliament and the Commission, to work together in pursuit of the European project – but also because of its content, since it identifies the obligations of the parties so that they can better confront the challenges of the future and resolve the problems of the citizenry.

– (PT) I welcome the motion for a resolution, which was approved today, on a new political Framework Agreement which will govern the institutional relations between the European Commission and the European Parliament and which will strengthen the powers of Parliament conferred by the Lisbon Treaty.

(Return tabled) Question No. 125 Mr. Dennis Bevington: With respect to the Building Canada Plan (2007-2014): (a) under the Building Canada Fund, (i) what projects have been approved for funding to date, (ii) where are they located, (iii) who are the partners involved, (iv) what is the federal contribution, (v) what are each partner's contribution, (vi) has the funding flowed; (b) under the Public-Private Partnerships Fund, (i) what projects have been approved for funding to date, (ii) where are they located, (iii) who are the partner ...[+++]s involved, (iv) what is the federal contribution, (v) what are each partner's contribution, (vi) has the funding flowed; (c) under the Gateways and Border Crossings Fund, (i) what projects have been approved for funding to date, (ii) where are they located, (iii) who are the partners involved, (iv) what is the federal contribution, (v) what are each partner's contribution, (vi) has the funding flowed; (d) under the Asia-Pacific Gateway and Corridor Initiative, (i) what projects have been approved for funding to date, (ii) where are they located, (iii) who are the partners involved, (iv) what is the federal contribution, (v) what are each partner's contribution, (vi) has the funding flowed; and (e) under the Provincial-Territorial Base Funding, (i) what projects have been approved for funding to date, (ii) where are they located, (iii) who are the partners involved, (iv) what is the federal contribution, (v) what are each partner's contribution, (vi) has the funding flowed?

[Text] Question No. 26 Mr. John Cummins: With regard to the risk management of the antimalarial drug mefloquine by Health Canada and the Department of National Defence: (a) what deployments since 1990 involved administration of the drug to members of the Canadian Forces; (b) did Health Canada receive from the Canadian Forces adverse drug event reports for each such deployment either during or immediately following deployment; (c) how many Canadians received the drug under Health Canada’s Lariam Safety Monitoring Study; (d) how many ...[+++] patients were the subject of monitoring reports received by Health Canada directly or indirectly from Roche under the Lariam Safety Monitoring Study; (e) what types of adverse events were identified by the Lariam Safety Monitoring Study up to the time the drug was licensed in 1993; (f) what is the total number of adverse events reported to Health Canada since the commencement of marketing in 1993; (g) how many adverse events were reported to Health Canada since the commencement of the marketing of the drug in 1993 involving each of the following reactions - hallucinations, panic reaction, hyper alertness, extreme excitability, convulsions, aggressive reaction, marked restlessness, suicide, suicidal tendency, suicide attempt, thoughts of self harm, abnormal dreams, emotional disorder, irritability, nightmares, abnormal thinking, anxiety, depressed state, aggravated depression, light-headedness, anxiety attack, mood swings, abnormal crying, psychosis, delusion, speech disorder, concentration impaired, fear, euphoria, hysteria, paranoid psychosis, memory impairment, emotional disorder, murder; (h) what measures have been taken by Health Canada to ensure that it receives notice of such adverse drug events from doctors administering the drug; (i) what changes to the product monograph have been approved by Health Canada since licensing of the drug in 1993; (j) how many Canadian Forces members deployed on special missions abroad since 1 ...